Zerlasiran, a short-interfering RNA, was well-tolerated and reduced time-averaged lipoprotein(a) [Lp(a)] concentration by more than 80% during 36 weeks of treatment in patients with atherosclerotic ...
Local BBC Radio joins BBC Radio 5 Live through the night on a weekday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback